1123 Immunocore
BioCentury & Getty Images

Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

Nov 23, 2020 | 11:59 PM GMT

With a positive Phase III readout in metastatic uveal melanoma, Immunocore has become the first company to solve one of the biggest challenges in immuno-oncology: applying T cell-engaging bispecifics to solid tumors. 

The data suggest an alternative bispecific structure, which uses

Read the full 652 word article

How to gain access

Continue reading with a
two-week free trial.